Is imatinib mesylate a promising drug in scleroderma due to extensive chronic graft-versus-host disease?
Papadakis
Vassilios
V
Department of Pediatric Hematology-Oncology, Agia Sofia Children's Hospital, Athens, Greece. vpapadak@otenet.gr
Karakasis
Dimitri
D
Sfikakis
Petros P
PP
Baltadakis
Ioannis
I
Apostolidis
John
J
Evangelou
Kostas
K
Gorgoulis
Vassilis G
VG
Harhalakis
Nikolaos
N
D001549:Benzamides; D002908:Chronic Disease; D005260:Female; D006086:Graft vs Host Disease / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications; D015477:Leukemia, Myelomonocytic, Chronic / Q000150:complications; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects; D010879:Piperazines; D011743:Pyrimidines; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate